

Under the Paperwork Reduction Project of 1999, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/731,375
Filing Date	December 8, 2003
First Named Inventor	Philip J. BARR
Art Unit	1617
Examiner Name	Jennifer M. KIM
Attorney Docket Number	39042.0014

Sheet

1

of

2

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known) ²	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
✓	A1	5,780,440	07-14-1998	Lezdey <i>et al.</i>	
	A2	5,532,215	07-02-1996	Lezdey <i>et al.</i>	
	A3	5,492,889	02-20-1996	Lezdey <i>et al.</i>	
	A4	5,346,886	09-13-1994	Lezdey <i>et al.</i>	
	A5	5,215,965	06-01-1993	Lezdey <i>et al.</i>	
	A6	5,190,917	03-02-1993	Lezdey <i>et al.</i>	
	A7	5,166,134	11-24-1992	Lezdey <i>et al.</i>	
	A8	5,134,119	07-28-1992	Lezdey <i>et al.</i>	
	A9	5,093,316	03-03-1992	Lezdey <i>et al.</i>	
	A10	5,679,665	10-21-1997	Bergamini <i>et al.</i>	
	A11	5,631,241	05-20-1997	della Valle <i>et al.</i>	
	A12	5,604,201	02-28-1997	Thomas <i>et al.</i>	
	A13	5,166,331	11-24-1992	Della Valle <i>et al.</i>	
	A14	5,061,729	10-29-1991	Kincses <i>et al.</i>	
	A15	4,474,751	10-02-1984	Haslam <i>et al.</i>	
	A16	4,025,620	05-24-1977	Beyer <i>et al.</i>	
	A17				
	A18				
	A19				

EXAMINER SIGNATURE

DATE CONSIDERED

6/23/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/731,375
				Filing Date	December 8, 2003
				First Named Inventor	Philip J. BARR
				Art Unit	1617
				Examiner Name	Jennifer M. KIM
Sheet	2	of	2	Attorney Docket Number	39042.0014
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	C1	Reexamination control no. 90/007215. Third Party Request for ex parte reexamination of U.S. Pat. No. 6,174,859			
	C2	Reexamination control no. 90/007215: Order granting reexamination of U.S. Pat. No. 6,174,859			
	C3	Reexamination control no. 90/007215: Patent owner statement under 37 C.F.R. § 1.530			
	C4	Reexamination control no. 90/007215: Third Party Requester Reply under 37 C.F.R. § 1.535			
/	C5	ABRAHAM et al., "Mast cells in infection and immunity," <i>Infect. Immun.</i> 65:3501-3508 (1997)			
/	C6	AVIDANO et al., "Analysis of protease activity in human otitis media," <i>Otolaryngology - Head and Neck Surgery</i> , 119(4):246 - 351 (October 1998)			
/	C7	BAYER CORPORATION. Alpha1-Proteinase Inhibitor (Human). Prolastin®. Revised March 2003.			
/	C8	BOYCE, "Mast cells: beyond IgE", <i>J. Allergy Clin. Immunol.</i> 111:24-32 (2003)			
/	C9	CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC). "Swimmer's Ear" (Otitis Externa). Fact-Sheet for Swimmers. Date unknown. <i>no date</i>			
/	C10	COAN et al., "Preparation and Properties of Alpha1-Proteinase Inhibitor Concentrate from Human Plasma," <i>Vox. Sang.</i> 48:333-342 (1985)			
/	C11	FDA, "Electronic Orange Book", excerpts (downloaded 03-16-2005)			
/	C12	FORNEY et al., "Anticryptosporidial potential of alpha-1-antitrypsin," <i>J. Eukaryot. Microbiol.</i> 43(5):63S (Sept-Oct 1996)			
/	C13	FORNEY et al., "Synergistic anticryptosporidial potential of the combination of alpha-1-antitrypsin and paromomycin," <i>Antimicrobial Agents Chemother.</i> , Sept. 1997, p. 2006 - 2008			
/	C14	GALLI et al., "Mast cells to the defense," <i>Nature Immunol.</i> 4:1160-1162 (2003)			
/	C15	MATZ et al., "Ototoxicity of ototopical antibiotic drops in humans," <i>Otolaryngol. Head neck Surg.</i> 130:S79-S82 (2004)			
/	C16	ROLAND et al., "Animal ototoxicity of topical antibiotics and the relevance to clinical treatment of human subjects," <i>Otolaryngol. Head neck Surg.</i> 130:S57-S78 (2004)			
EXAMINER SIGNATURE				DATE CONSIDERED 6/23/05	